Laury Adrienne M, Schlosser Rodney J, Wise Sarah K
Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, Georgia 30308, USA.
Curr Opin Otolaryngol Head Neck Surg. 2013 Jun;21(3):252-5. doi: 10.1097/MOO.0b013e32835fcb22.
Sublingual immunotherapy (SLIT) has been shown to be a new and promising treatment for people with various allergic syndromes. Several studies have examined its efficacy. However, significantly fewer investigations have explored its specific impact on the patient's quality of life (QOL).
SLIT has an excellent safety profile, superior in many ways to subcutaneous immunotherapy (SCIT). Additionally, SLIT significantly decreases the use of allergy medications, as well as decreasing the money spent on allergy symptom control. Finally, SLIT has been shown to improve the patient's QOL when compared to placebo or even second-generation antihistamines.
Increasing data support the use of SLIT as a well tolerated, cost-effective, and time-efficient modality for the treatment of multiple allergic syndromes. However, additional studies are needed, particularly QOL studies which compare SLIT to the FDA-approved SCIT.
舌下免疫疗法（SLIT）已被证明是一种治疗各种过敏综合征的新的、有前景的疗法。多项研究已对其疗效进行了检验。然而，探究其对患者生活质量（QOL）具体影响的研究要少得多。
SLIT具有出色的安全性，在许多方面优于皮下免疫疗法（SCIT）。此外，SLIT能显著减少过敏药物的使用，同时降低用于控制过敏症状的费用。最后，与安慰剂甚至第二代抗组胺药相比，SLIT已被证明能改善患者的生活质量。
越来越多的数据支持将SLIT作为一种耐受性良好、经济高效且节省时间的方法来治疗多种过敏综合征。然而，还需要更多研究，尤其是将SLIT与美国食品药品监督管理局（FDA）批准的SCIT进行比较的生活质量研究。
